Statin intolerance limits patients’ capacity to reach their LDL goals. This study compared the new drug alirocumab vs. ezetimibe in patients with statin intolerance and muscular symptoms (≥2 statin intolerance at minimum doses). Study design included placebo administration and statin intolerance testing. LDL baseline was 194 mg/dl.
Conclusion
Alirocumab reduced LDL levels significantly compared to ezetimibe after 24 weeks in a statin intolerant population with high baseline LDL levels. In addition, it showed a much lower tolerance rate compared to atorvastatin
2_patrick_moriarty
Patrick M Moriarty
2014-11-18
Original title: Efficacy And Safety of the Proprotein Convertase Subtilisin/kexin Type 9 Monoclonal Antibody, Alirocumab, versus Ezetimibe, in Patients With Statin Intolerance as Defined by a Placebo Run-in and Statin Rechallenge Arm.